These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30602158)

  • 1. pH-Dependent 5-Aminosalicylates Releasing Preparations Do Not Affect Thiopurine Metabolism.
    Takahashi K; Bamba S; Morita Y; Nishida A; Kawahara M; Inatomi O; Sugimoto M; Sasaki M; Andoh A
    Digestion; 2019; 100(4):238-246. PubMed ID: 30602158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients.
    Gao X; Zhang FB; Ding L; Liu H; Wang XD; Chen BL; Bi HC; Xiao YL; Zhao LZ; Chen MH; Huang M; Hu PJ
    Eur J Gastroenterol Hepatol; 2012 Aug; 24(8):958-64. PubMed ID: 22664938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of 5-aminosalicylic acid on 6-thioguanosine phosphate metabolite levels: a prospective study in patients under steady thiopurine therapy.
    de Graaf P; de Boer NK; Wong DR; Karner S; Jharap B; Hooymans PM; Veldkamp AI; Mulder CJ; van Bodegraven AA; Schwab M
    Br J Pharmacol; 2010 Jul; 160(5):1083-91. PubMed ID: 20590602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine.
    Hande S; Wilson-Rich N; Bousvaros A; Zholudev A; Maurer R; Banks P; Makrauer F; Reddy S; Burakoff R; Friedman S
    Inflamm Bowel Dis; 2006 Apr; 12(4):251-7. PubMed ID: 16633046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism.
    de Boer NK; Wong DR; Jharap B; de Graaf P; Hooymans PM; Mulder CJ; Rijmen F; Engels LG; van Bodegraven AA
    Am J Gastroenterol; 2007 Dec; 102(12):2747-53. PubMed ID: 17764493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
    Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
    J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine.
    Gerich ME; Quiros JA; Marcin JP; Tennyson L; Henthorn M; Prindiville TP
    J Crohns Colitis; 2010 Nov; 4(5):546-52. PubMed ID: 21122558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease.
    Haines ML; Ajlouni Y; Irving PM; Sparrow MP; Rose R; Gearry RB; Gibson PR
    Inflamm Bowel Dis; 2011 Jun; 17(6):1301-7. PubMed ID: 20812329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of Allopurinol for Altering Thiopurine Metabolism to Optimize Therapy in Patients with Inflammatory Bowel Disease.
    Wall GC; Muktar H; Effken C; Mahajan PB
    Pharmacotherapy; 2018 Feb; 38(2):259-270. PubMed ID: 29197117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease.
    Jharap B; de Boer NK; Stokkers P; Hommes DW; Oldenburg B; Dijkstra G; van der Woude CJ; de Jong DJ; Mulder CJ; van Elburg RM; van Bodegraven AA;
    Gut; 2014 Mar; 63(3):451-7. PubMed ID: 23424097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the use of metabolite measurement in children receiving treatment with a thiopurine.
    Armstrong L; Sharif JA; Galloway P; McGrogan P; Bishop J; Russell RK
    Aliment Pharmacol Ther; 2011 Nov; 34(9):1106-14. PubMed ID: 21929546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse Events of Thiopurine Therapy in Pediatric Inflammatory Bowel Disease and Correlations with Metabolites: A Cohort Study.
    Jagt JZ; Pothof CD; Buiter HJC; van Limbergen JE; van Wijk MP; Benninga MA; de Boer NKH; de Meij TGJ
    Dig Dis Sci; 2022 Jan; 67(1):241-251. PubMed ID: 33532972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of mesalazine formulations on thiopurine metabolism through thiopurine S-methyltransferase inhibition.
    Morikubo H; Kobayashi T; Ozaki R; Okabayashi S; Kuronuma S; Takeuchi O; Shiba T; Kiyohara H; Matsubayashi M; Sagami S; Nakano M; Ikezaki O; Hisamatsu T; Tanaka Y; Hibi T
    J Gastroenterol Hepatol; 2021 Aug; 36(8):2116-2124. PubMed ID: 33470487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease.
    Wong DR; Coenen MJ; Vermeulen SH; Derijks LJ; van Marrewijk CJ; Klungel OH; Scheffer H; Franke B; Guchelaar HJ; de Jong DJ; Engels LG; Verbeek AL; Hooymans PM;
    J Crohns Colitis; 2017 Feb; 11(2):175-184. PubMed ID: 27402913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy.
    Gilissen LP; Wong DR; Engels LG; Bierau J; Bakker JA; Paulussen AD; Romberg-Camps MJ; Stronkhorst A; Bus P; Bos LP; Hooymans PM; Stockbrügger RW; Neef C; Masclee AA
    J Crohns Colitis; 2012 Jul; 6(6):698-707. PubMed ID: 22398098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis.
    Wusk B; Kullak-Ublick GA; Rammert C; von Eckardstein A; Fried M; Rentsch KM
    Eur J Gastroenterol Hepatol; 2004 Nov; 16(12):1407-13. PubMed ID: 15618853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Thiopurine Metabolite Monitoring on the Durability of Thiopurine Monotherapy in Pediatric IBD.
    Spencer E; Norris E; Williams C; Dubinsky MC
    Inflamm Bowel Dis; 2019 Jan; 25(1):142-149. PubMed ID: 29920603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms.
    Stocco G; Cuzzoni E; De Iudicibus S; Favretto D; Malusà N; Martelossi S; Pozzi E; Lionetti P; Ventura A; Decorti G
    World J Gastroenterol; 2015 Mar; 21(12):3571-8. PubMed ID: 25834322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations.
    Curkovic I; Rentsch KM; Frei P; Fried M; Rogler G; Kullak-Ublick GA; Jetter A
    Eur J Clin Pharmacol; 2013 Aug; 69(8):1521-31. PubMed ID: 23588559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between 6-mercaptopurine dose and 6-thioguanine nucleotide levels in patients with inflammatory bowel disease.
    Morales A; Salguti S; Miao CL; Lewis JD
    Inflamm Bowel Dis; 2007 Apr; 13(4):380-5. PubMed ID: 17206711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.